MGNX
NASDAQ
$4.32
Macrogenics Inc (MGNX)
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $6.75 (+56.25%)
Market Cap
$275M
Free Cash Flow Yield
-26.11%
Beta (5Y)
1.46
Price Chart
Valuation
Market Cap$275M
Forward P/E60.98
P/S1.74
P/B13.49
Profitability
Total Revenue (TTM)$157M
Gross Profit (TTM)-$26M
EBITDA-$57M
Profit Margin-44.8%
Operating Margin-161%
EPS-$1.11
Financial Health
Free Cash Flow Yield-26.11%
Growth & Risk
EPS 5Y CAGR-14.38%
Revenue 5Y CAGR+7.76%
FCF 5Y CAGR-6.82%
Beta (5Y)1.46
Sharpe Ratio1.51